Eczema Flare in Pregnancy: Topical & Systemic Treatment Guide

TL;DR

• Atopic dermatitis is the most common inflammatory skin condition in pregnancy, affecting up to 1 in 5 pregnant individuals with pre-existing eczema who experience flares.
• Emollients remain first-line — liberal, fragrance-free application is both safe and effective throughout all trimesters.
• Low-to-moderate potency topical corticosteroids (e.g., hydrocortisone, mometasone furoate) are considered safe when used appropriately; avoid potent/very potent agents on large areas.
• Cyclosporine is the systemic immunosuppressant with the most pregnancy safety data and may be used for severe, refractory disease.
• Dupilumab (Dupixent) lacks robust controlled pregnancy data; current registries are reassuring but insufficient to recommend routine use.

Why Eczema Flares During Pregnancy

Pregnancy profoundly reshapes the maternal immune system. The physiologic shift toward T-helper 2 (Th2)–dominant immunity — designed to prevent fetal rejection — inadvertently amplifies the same immunologic pathway that drives atopic dermatitis (AD). This explains why eczema treatment pregnancy concerns rank among the most common dermatology consultations in obstetric practice.

Epidemiologic data suggest that AD accounts for roughly 36–49% of all pregnancy-related dermatoses. Approximately one-third of women with pre-existing AD experience worsening during pregnancy, most commonly in the second and third trimesters. A smaller proportion develop atopic eczema for the first time during gestation.

The hormonal milieu further complicates matters. Rising progesterone and estrogen levels alter skin barrier function, increase transepidermal water loss, and may heighten itch perception. Stress, sleep disruption, and the discontinuation of previously effective medications at conception all contribute to the perfect storm of a pregnancy flare.

Atopic Eruption of Pregnancy: Getting the Diagnosis Right

In 2006, Ambros-Rudolph and colleagues proposed consolidating several pregnancy-specific eczematous conditions under the umbrella term atopic eruption of pregnancy (AEP). This classification encompasses:

• Eczema in pregnancy (pre-existing AD that worsens, or new-onset AD triggered by pregnancy)
• Prurigo of pregnancy (discrete excoriated papules on extensor limbs and trunk)
• Pruritic folliculitis of pregnancy (widespread follicular papules)

AEP typically presents before the third trimester — an important distinguishing feature from polymorphic eruption of pregnancy (PEP/PUPPP), which usually appears in late pregnancy and follows striae. AEP carries no increased risk of adverse fetal outcomes, unlike pemphigoid gestationis or intrahepatic cholestasis of pregnancy, both of which require urgent differentiation.

Key Differential Diagnoses in Pregnancy Dermatoses

Clinical pearl: If a pregnant patient presents with widespread pruritus and no primary skin lesion, always check serum bile acids before attributing symptoms to eczema.

First-Line Therapy: Emollients and Skin Care

The foundation of eczema management does not change in pregnancy. Emollients are safe, effective, and should be used liberally — at least 250–500 g per week for widespread disease, according to British Association of Dermatologists (BAD) guidance.

Practical Emollient Recommendations

• Choose fragrance-free, preservative-minimal formulations. Ointments (e.g., emulsifying ointment, white soft paraffin) provide superior barrier repair but may feel greasy; creams are more cosmetically acceptable in warmer months.
• Apply within 3 minutes of bathing to lock in moisture.
• Use emollients as soap substitutes. Conventional soaps and shower gels strip the skin barrier and can trigger flares.
• Avoid aqueous cream BP as a leave-on emollient — it contains sodium lauryl sulfate, which can paradoxically damage the skin barrier with repeated application.
• Wet wraps (emollient under damp tubular bandages) can provide rapid relief during acute flares without systemic drug exposure.

Emollient therapy alone can reduce topical corticosteroid requirements by 50% or more and should be continued even when the skin appears clear.

Topical Corticosteroids: Navigating Safety in Pregnancy

Topical corticosteroids remain the pharmacologic backbone of AD management across all patient populations, and pregnancy is no exception. The challenge lies in balancing disease control against perceived teratogenic risk — a perception that is, for most agents, substantially overstated.

What the Evidence Shows

The most comprehensive safety data come from the 2015 Cochrane systematic review by Chi et al. and a subsequent population-based cohort study analysing over 2,500 pregnancies exposed to topical corticosteroids. Key findings include:

• No association between topical corticosteroid use and congenital malformations, cleft lip/palate, preterm delivery, or low birth weight — for mild-to-moderate potency agents.
• Potent and very potent topical corticosteroids (e.g., clobetasol propionate, betamethasone dipropionate) used in large quantities (>300 g total during pregnancy) showed a possible association with low birth weight in one cohort study, though this finding was not consistently replicated.
• The absolute risk, even in the high-exposure group, remained small, and confounding by disease severity could not be fully excluded.

Topical Corticosteroid Potency and Pregnancy Safety

Practical Prescribing Principles

• Use the fingertip unit (FTU) system to guide quantity: one FTU (≈0.5 g) covers an area the size of two adult palms.
• Step-down approach: start at adequate potency to achieve control within 7–14 days, then step down to a milder agent or maintenance regimen (e.g., twice-weekly application to previously affected areas).
• Do not under-treat out of excessive caution. Poorly controlled eczema causes significant maternal morbidity — sleep deprivation, secondary infection risk, and psychological distress — which themselves carry pregnancy implications.
• Apply topical corticosteroids before emollients, or leave a 15–30 minute gap between the two.

Topical Calcineurin Inhibitors: Tacrolimus and Pimecrolimus

Tacrolimus ointment (Protopic) and pimecrolimus cream (Elidel) are steroid-sparing alternatives widely used in non-pregnant patients. Their pregnancy safety profile is less well-established than that of topical corticosteroids, but the available data are reassuring:

• Systemic absorption from topical application is minimal (blood levels typically undetectable or well below therapeutic thresholds for systemic tacrolimus).
• Animal studies at supratherapeutic systemic doses showed fetal toxicity, but relevance to topical human use is limited.
• Small case series and registry data have not identified a signal for malformations or adverse pregnancy outcomes.

Current positioning: BAD and most expert consensus panels consider topical calcineurin inhibitors a reasonable second-line option in pregnancy, particularly for sensitive areas (face, eyelids, genital skin) where prolonged corticosteroid use risks skin atrophy. They are not, however, first-line due to the comparatively limited safety database.

Both agents carry an FDA boxed warning regarding theoretical lymphoma risk — a concern that has not been substantiated in post-marketing surveillance spanning over two decades of use.

Systemic Therapy for Severe Pregnancy Eczema

When topical measures fail to control widespread or debilitating AD in pregnancy, systemic therapy becomes necessary. The decision is never taken lightly, but the consequences of untreated severe eczema — secondary staphylococcal infection, eczema herpeticum, profound sleep disruption, and maternal distress — must be weighed against drug exposure risk.

Cyclosporine

Cyclosporine (ciclosporin) is the systemic agent with the most reassuring pregnancy safety data for atopic dermatitis. Originally studied extensively in transplant recipients, its pregnancy profile includes:

• No increase in congenital malformations above baseline population rates across multiple registries and meta-analyses.
• A modest association with prematurity and lower birth weight, though confounded by the underlying conditions (e.g., organ transplantation, autoimmune disease) requiring its use.
• Recommended dosing for AD in pregnancy: 2–5 mg/kg/day in two divided doses, using the lowest effective dose for the shortest practical duration.

Monitoring requirements: blood pressure and renal function (serum creatinine) every 2 weeks during initiation, then monthly. Cyclosporine does not require avoidance of breastfeeding — LactMed notes that infant exposure via breast milk is low and no adverse effects have been reported in breastfed infants of treated mothers.

Systemic Corticosteroids

Short courses of oral prednisolone (e.g., 0.5 mg/kg/day for 5–7 days, tapering over 2–3 weeks) are sometimes used for acute severe flares. Key considerations:

• First trimester: a small increased risk of oral cleft has been reported with systemic corticosteroid use in the first trimester (odds ratio approximately 1.3–1.4), though the absolute risk remains low (approximately 1–2 additional cases per 1,000 exposed pregnancies).
• Third trimester: prolonged use raises concerns for maternal gestational diabetes, hypertension, and neonatal adrenal suppression.
• Position: reasonable as a short bridge while initiating cyclosporine or optimising topical therapy, but not suitable for long-term management.

Agents to Avoid in Pregnancy

Dupilumab (Dupixent): Emerging Data

Dupilumab, the anti–IL-4 receptor alpha monoclonal antibody that has transformed AD management, presents a nuanced situation in pregnancy:

• As a large IgG4 monoclonal antibody, placental transfer is minimal in the first trimester but increases substantially during the second and third trimesters.
• The manufacturer-sponsored DUMBRELLA pregnancy registry and other prospective observational data have not identified a pattern of malformations or adverse fetal outcomes, but sample sizes remain limited.
• FDA pregnancy labelling (FDAAA): no adequate and well-controlled studies in pregnant women. Animal reproduction studies at doses up to 10× the maximum recommended human dose showed no evidence of harm.
• Current expert consensus (including BAD 2024 guidance): dupilumab may be continued in pregnancy when the clinical benefit clearly outweighs potential risks, particularly in patients with severe disease who are well-controlled on dupilumab and have no suitable alternative. Ideally, this decision is made before conception.

In practice: starting dupilumab de novo in pregnancy is not recommended by most guidelines. Continuing a pre-existing prescription with informed consent and shared decision-making is a different clinical scenario and may be appropriate.

Monitoring, Safety Red Flags, and When to Escalate

Signs Requiring Urgent Medical Review

• Weeping, crusted, or rapidly spreading lesions — consider secondary bacterial infection (impetiginised eczema) requiring topical or systemic antibiotics.
• Clustered vesicles on an eczematous base — suspect eczema herpeticum (Kaposi varicelliform eruption), a dermatological emergency requiring intravenous aciclovir.
• Generalised pruritus without visible rash — rule out intrahepatic cholestasis of pregnancy (check serum bile acids).
• Tense blisters, especially periumbilical — consider pemphigoid gestationis; request direct immunofluorescence.
• Erythroderma (>90% body surface area involvement) — rare but life-threatening; requires inpatient management.
• Significant psychological distress, sleep deprivation affecting daily function — under-treated eczema in pregnancy is not a trivial condition; escalate to specialist care.

Monitoring Schedule for Systemic Therapy in Pregnancy

Special Considerations: Lactation

Most topical and several systemic treatments can be continued during breastfeeding with appropriate precautions.

Topical corticosteroids: safe during breastfeeding. Avoid application directly to the nipple/areola immediately before feeds; if applied to the breast, wipe gently before nursing.

Topical calcineurin inhibitors: tacrolimus and pimecrolimus are acceptable during lactation given minimal systemic absorption. Do not apply to the breast.

Cyclosporine: per LactMed, concentrations in breast milk are low and the estimated infant dose is well below therapeutic levels. The American Academy of Pediatrics (AAP) does not list cyclosporine as contraindicated during breastfeeding, though infant monitoring (growth, renal function if prolonged exposure) is prudent.

Dupilumab: limited lactation data. As an IgG4 antibody, it is expected to be present in breast milk in small quantities, and large proteins are generally poorly absorbed from the neonatal gastrointestinal tract. LactMed does not report adverse effects in breastfed infants, but data are sparse.

Oral prednisolone: at doses ≤20 mg/day, infant exposure is negligible. At higher doses, waiting 3–4 hours after dosing before feeding can further reduce infant exposure.

Frequently Asked Questions

Is hydrocortisone cream safe throughout all trimesters?

Yes. Hydrocortisone 0.5–1% is the mildest topical corticosteroid and has extensive safety data in pregnancy. It can be used on the face, flexures, and body throughout all three trimesters without demonstrated fetal risk. The key limitation is efficacy — it may be insufficient for moderate-to-severe eczema on the body, where a moderate-potency agent may be needed.

Can I use Dermovate (clobetasol) while pregnant?

Clobetasol propionate is a very potent topical corticosteroid. It is not absolutely contraindicated in pregnancy, but should be used sparingly — limited areas, short courses (typically ≤2 weeks), and under specialist guidance. The concern arises with large cumulative quantities (>300 g over the pregnancy), which have been associated with possible reductions in birth weight. For most patients, a moderate-potency agent will suffice.

What natural remedies help pregnancy eczema?

The most effective non-pharmacologic intervention is rigorous emollient use and trigger avoidance. Lukewarm (not hot) baths with colloidal oatmeal can provide temporary itch relief. Wearing loose cotton clothing and maintaining cool indoor temperatures help. Evening primrose oil and probiotics have been studied, but neither has sufficient evidence to recommend for eczema treatment in pregnancy based on current Cochrane reviews. Avoid unregulated herbal preparations, as these may contain undisclosed ingredients with unknown safety profiles.

My dermatologist wants to start cyclosporine — is that safe for my baby?

Cyclosporine has been used in pregnant transplant recipients for decades. The accumulated evidence does not show an increased risk of birth defects. There is a modest association with prematurity and lower birth weight, but these outcomes are difficult to separate from the effects of the underlying condition being treated. When severe eczema is not controlled by topical therapy, the maternal risks of untreated disease (infection, sleep deprivation, psychological harm) must be balanced against this small potential risk. Your dermatologist and obstetrician should coordinate care.

Should I stop dupilumab if I find out I'm pregnant?

This decision should be individualised. Current evidence does not indicate harm, but data are limited. If your eczema is well-controlled on dupilumab and alternatives (cyclosporine, topical intensification) are unlikely to maintain control, continuing dupilumab may be reasonable after a thorough risk-benefit discussion. If your disease is mild-to-moderate and can be managed topically, discontinuation with transition to topical therapy is a reasonable approach. Do not stop any medication abruptly without medical guidance.

Does pregnancy eczema affect the baby?

Atopic eruption of pregnancy itself does not cause direct fetal harm. However, secondary complications of poorly managed eczema — such as widespread skin infection, sleep deprivation affecting maternal health, and the stress of uncontrolled disease — can indirectly impact pregnancy well-being. There is also epidemiologic evidence that parental atopy increases the child's risk of developing atopic conditions, but this is a genetic predisposition, not a consequence of the pregnancy flare itself.

Can I use antihistamines for itch?

First-generation antihistamines (chlorphenamine, diphenhydramine) have an extensive safety record in pregnancy and can help with nocturnal itch through their sedating properties. Second-generation antihistamines (cetirizine, loratadine) also appear safe based on large surveillance studies and are preferred during the daytime as they are non-sedating. Note that antihistamines have limited efficacy for eczema-related itch, which is primarily non-histaminergic; their main benefit is facilitating sleep.

When should I see a specialist rather than manage this with my GP?

Referral to dermatology is appropriate when: topical corticosteroids of moderate potency used correctly for 2–4 weeks have not achieved adequate control; secondary infection is recurrent; the diagnosis is uncertain (especially if onset is in the third trimester or blisters are present); systemic therapy is being considered; or the condition is significantly affecting quality of life, sleep, or mental health.

References

1. Chi CC, Wang SH, Wojnarowska F, Kirtschig G, Davies E, Bennett C. Safety of topical corticosteroids in pregnancy. Cochrane Database Syst Rev. 2015;(10):CD007346. Cochrane Library

2. Ambros-Rudolph CM, Müllegger RR, Vaughan-Jones SA, Kerl H, Black MM. The specific dermatoses of pregnancy revisited and reclassified. J Am Acad Dermatol. 2006;54(3):395–404. PMID: 16488288

3. Chi CC, Wang SH, Charles-Holmes R, et al. Pemphigoid gestationis: early onset and blister formation are associated with adverse pregnancy outcomes. Br J Dermatol. 2009;160(6):1222–1228. PMID: 19298272

4. Drugs and Lactation Database (LactMed). National Institute of Child Health and Human Development. LactMed

5. FDA. Prescribing information: Dupixent (dupilumab). 2024. FDA Label

6. NICE. Atopic eczema in under 12s: diagnosis and management. Clinical guideline CG57. 2007 (updated 2023). NICE CG57

7. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71(8):1051–1055. PMID: 11374400

8. Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. J Eur Acad Dermatol Venereol. 2019;33(9):1644–1659. PMID: 31231880

9. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70(3):401.e1–14. PMID: 24528911

10. Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women. J Am Acad Dermatol. 2012;67(3):459–477. PMID: 22018758

About the Author

Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with 15 years of experience spanning hospital pharmacy, medication safety, and drug information services. He specialises in evidence-based medication reviews with particular interest in dermatologic pharmacotherapy and the safe use of medications during pregnancy and lactation. Dr. Ozarchuk writes for PillsCard.com, where he translates complex pharmaceutical evidence into accessible guidance for patients and healthcare professionals worldwide.

Medical Disclaimer

This article is provided for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. The information presented reflects current evidence as of the date of publication but may not capture the most recent research developments. Pregnancy and lactation present unique clinical considerations that require individualised assessment. Do not start, stop, or change any medication — including over-the-counter products — without consulting your prescriber, obstetrician, or pharmacist. Always seek the advice of a qualified healthcare professional with any questions regarding a medical condition or treatment. PillsCard.com and its authors assume no liability for actions taken based on the content of this article.